Corcept Therapeutics (CORT)
(Delayed Data from NSDQ)
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.75 USD
+0.47 (1.02%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $46.78 +0.03 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth C Momentum F VGM
Zacks News
Wall Street Analysts Think Corcept (CORT) Could Surge 41.31%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alnylam Pharmaceuticals (ALNY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
Here's Why Momentum in Corcept (CORT) Should Keep going
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Corcept (CORT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Corcept (CORT) Moves 6.5% Higher: Will This Strength Last?
by Zacks Equity Research
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Do Options Traders Know Something About Corcept (CORT) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Corcept (CORT) stock based on the movements in the options market lately.
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
by Zacks Equity Research
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept Shares Rise More Than 45% in Six Months: Here's Why
by Zacks Equity Research
CORT's Cushing's syndrome drug, Korlym, has been performing well. The NDA for lead candidate, relacorilant, in Cushing's syndrome will be filed shortly.
Corcept (CORT) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Upgraded to Buy: Here's Why
by Zacks Equity Research
Corcept (CORT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Janus Henderson Small Cap Growth Alpha ETF (JSML) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JSML
Should Janus Henderson Small Cap Growth Alpha ETF (JSML) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JSML
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
by Zacks Equity Research
Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.
Wall Street Analysts Believe Corcept (CORT) Could Rally 70.58%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 70.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
5 Small Drug Stocks to Buy as Innovation Reaches Peak
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FBT
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
by Zacks Equity Research
Sector ETF report for FBT
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Corcept Therapeutics Incorporated (CORT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Corcept (CORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's What Could Help Corcept (CORT) Maintain Its Recent Price Strength
by Zacks Equity Research
Corcept (CORT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Can Corcept (CORT) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Corcept (CORT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are You Looking for a Top Momentum Pick? Why Corcept Therapeutics (CORT) is a Great Choice
by Zacks Equity Research
Does Corcept Therapeutics (CORT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 37.6% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Corcept (CORT) delivered earnings and revenue surprises of 39.13% and 6.41%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
by Zacks Equity Research
Bristol-Myers (BMY) posts impressive second-quarter results, with both earnings and sales beating their respective estimates. The company also raises its annual earnings guidance.